Ex vivo expansion of hematopoietic precursor cells

Current Opinion in Hematology

Volumn 3, Issue 3, 1996, Pages 235-240

  Brugger, Wolfram ^a   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6;

CANCER CHEMOTHERAPY; DENDRITIC CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029900691     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603030-00012     Document Type: Review

References (46)

1. + cells from patients with stage IV breast cancer. Blood 1994, 84:3567-3574. Describes the optimization of the culture conditions for the ex vivo expansion of hematopoietic progenitor cells for a potential clinical use.
2. + cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells. Blood 1995, 86:958-970.
3. Davis TA, Robinson DH, Lee KP, Kessler SW: Porcine brain microvascular endothelial cells support the in vitro expansion of human primltive hematopoietic bone marrow progenitor cells with a high replating potential: requirement for cell-to-cell contact interactions and colony-stimulating factors. Blood 1995, 85:1751-1761.
4. Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman RL, Moore MAS, Asch • AS: Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995, 86:3353-3363. The use of isolated human bone marrow microvascular endothelial cells for the ex vivo expansion of hematopoietic progenitor cells is described. The authors show that progenitor cells can be expanded on endothelial cells without exogenous growth factors.
5. Keller JR, Ortiz M, Ruscetti FW: Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. Blood 1995, 86:1757-1764.
6. + cell population from cord blood vs. adult bone marrow. Exp Hematol 1995, 23:1289-1295.
7. Bertolini F, Soligo D, Lazzari L, Corsini C, Servida F, Sirchia G: The effect of interleukin-12 in ex vivo expansion of human haemopoietic progenitors. Br J Haematol 1995, 90:935-938.
8. Xi X, Schlegel N, Caen JP, Minty A, Fournier S, Caput D, Ferrara P, Han ZC: Differential effects of recombinant human interleukin-13 on the in vitro growth of human haemopoietic progenitor cells. Br J Haematol 1995, 90:921-927.
9. Jacobsen FW, Keller JR, Ruscetti FW, Veiby OP, Jacobsen SEW: Direct synergstic effects of IL-4 and IL-11 on proliferation of primitive hematopoietic progenitor cells. Exp Hematol 1995, 23:990-995.
10. + cell populations.
11. Lyman SD, James L, Vanden Bos T, deVries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FA, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP: Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993, 75:1157-1167.
12. Broxmeyer HE, Lu L, Cooper S, Ruggierei L, Li ZH, Lymann SD: Flt3 lig•and stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995, 23:1121-1129. This is one of the first reports describing the efficacy of flt3 ligand in terms of proliferation and differentiation of primitive hematopoietic progenitor cells in combination with several other growth factors.
13. Jacobson SEW, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD: The •• flt3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995, 181:1357-1363. Flt3 ligand preferentially supports the ex vivo expansion of primitive progenitor cells, particularly when combined with growth factors of the hematopoietin superfamily. Less potent synergy was observed with ligands signaling through other members of the tyrosine kinase receptors.
14. Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes LA, Rennick D: Flt3/flk2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 1995, 85:2747-2755.
15. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, •• Vitelli L, Barberi T, Testa U, Lyman S, Peschle C: Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995, 86:1661-1670. Describes the synergistic effects of flt3 ligand for the ex vivo expansion of very primitive progenitor/stem cells. Also shows that erythroid proliferation is not synergistically affected by flt3 ligand.
16. + cells in serum-free cultures containing Steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential. Blood 1994, 83:128-136.
17. + peripheral blood progenitor cells under different growth factor combinations was investigated for their ability to possibly expand long-term culture-initiating cells. It has been shown that a combination of stem cell factor, interleukin-1, interleukin-3, interleukin-6, and erythropoietin maintains the number of long-term culture-initiating cells, but none of the cytokine combinations tested was able to significantly expand long-term culture-initiating cells.
18. + cells) for the ex vivo expansion of long-term culture-initiating cells. Several factors were shown to affect the generation of long-term culture-initiating cells ex vivo, with stroma, accessory cells, and frequent medium exchange being most important. Under these conditions, a 3.5-fold amplification of long-term culture-initiating cells could be observed.
19. Kaufmann CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone-marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994, 84:2436-2446.
20. Sui X, Tsuji K, Tanaka R, Tajima S, Muraoka K, Ebihara Y, Ikebuchi K, •• Yasukawa K, Taga T, Kishimoto T, Nakahata T: gp130 and c-kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci U S A 1995, 92:2859-2863. Describes a novel approach for the ex vivo expansion of hematopoietic progenitor cells using gp130 and c-kit signaling. This method might be particularly useful for the expansion of the most primitive progenitor cells ex vivo.
21. Kishimoto T, Taga T, Akira S: Cytokine signal transduction. Cell 1994, 76:253-262.
22. Mackensen A, Herbst B, Köhler G, Wolff-Vorbeck G, Rosenthal FM, Veelken H, Kulmburg P, Schaefer HE, Mertelsmann R, Lindemann A: Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood 1995, 86:2699-2707.
23. + progenitor cells is described. Moreover, the functional capabilities of these cells were investigated in mixed lymphocyte reactions.
24. + cells for a potential clinical application.
25. + hematopoietic progenitor cells in cancer patients. Eur J Immunol 1996, 26.
26. + cord blood cells stimulated with stem cell factor and interleukin-3. Blood 1994, 84:3667-3674.
27. Nagler A, Eldor A, Naparstek E, Mumcuoglu M, Slavin S, Deutsch VR: Ex vivo expansion of megakaryocyte precursors by preincubatlon of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro. Exp Hematol 1995, 23:1268-1274.
28. + cell expansion and expression of lineage markers during liquid culture of human progenitor cells. Stem Cells 1995, 13:167-174.
29. Schattner M, Lefebvre P, Spanier Mingolelli S, Goolsby CL, Rademaker A, White JG, Foster D, Cohen I: Thrombopoietin stimulated ex vivo expansion of megakaryocytes in human bone marrow. Blood 1995, 86:368a.
30. + cells. Blood 1995, 86:231a.
31. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Wed 1994, 179:1109-1118.
32. Scheding S, Franke H, Brugger W, Kanz L, Schmitz S: How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after high-dose chemotherapy and peripheral blood progenitor cell transplantation? Blood 1995, 86:224a
33. Muench MO, Moore MAS: Accelerated recovery of peripheral blood cell counts in mice transplanted with in vitro cytokine-expanded hematopoietic progenitors. Exp Hematol 1992, 20:611-619.
34. d mice as a single factor. Blood 1992, 79:913.
35. Muench MO, Firpo MT, Moore MAS: Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferation potential. Blood 1993, 81:3463-3473.
36. Knobel KM, McNally MA, Berson AE, Rood D, Chen K, Kilinski L, Tran K, Okarma TB, Lebkowski JS: Long-term reconstitution of mice after ex vivo expansion of bone marrow cells: differential activity of cultured bone marrow and enriched stem cell populations. Exp Hematol 1994, 22:1227-1235.
37. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ: Murine • marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 1995, 23:461-469. Demonstrates an engraftment defect of ex vivo expanded murine progenitor cells when compared with normal bone marrow cells after transplantation into nonablated hosts. These data suggest that cytokine-mediated expansion of hematopoietic progenitor cells might impair their capacity for long-term hematopoiesis.
38. + cells/patient was used to generate sufficient numbers of progenitor cells in stem cell factor, interleukin-1-, interleukin-3-, interleukin-6-, and erythropoietin-supported liquid cultures. Short-term hematopoietic recovery after high-dose chemotherapy was rapid, although long-term hematopoietic effects of ex vivo expanded progenitors could not be studied here, because endogenous recovery was likely to occur after autologous transplantation.
39. Champlin R, Mehra R, Gajewski J, Khouri I, Geisler D, Davis M, Oba K, Thoomas M, Armstrong RD, Douville J, Weber S, Silver S, Muller T, Deisseroth A: Ex vivo expanded progenitor cell transplantation in patients with breast cancer. Blood 1995, 86:295a.
40. + cells: feasibility and safety associated with clinical use. Blood 1995, 86:294a.
41. Holyoake TL, Alcorn MJ, Richmond L, Pearson C, Farrell E, Kyle B, Dunlop DJ, Fitzsimons E, Steward WP, Pragnell IB: A phase I study to evaluate the safety of re-infusing CD34 cells expanded ex vivo as part of all or a PBPC transplant procedure. Blood 1995, 86:294a.
42. Kessinger A: Circulating stem cells: waxing hematopoietic. N Engl J Med 1995, 333:315-316.
43. + cells.
44. + peripheral blood stem cells (PBSC) in older patients with advanced hematologic mallgnancy. Blood 1995, 86:389a.
45. + progenitor cells. Blood 1995, 86:295a.
46. Bock TA, Orlic D, Dunbar CE, Broxmeyer HE, Bodine DM: Improved • engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med 1995, 182:2037-2043. Describes a novel in vivo stem cell assay using mice with severe combined immunodeficiency carrying human cytokine transgenes for GM-CSF, interleukin-3, and stem cell factor.